MedTrace Logo

Zylet vs TobraDex in Blepharokeratoconjunctivitis

NCT00447577 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2011-12-09

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis

Conditions

  • Blepharokeratoconjunctivitis

Interventions

DRUG

Loteprednol etabonate and tobramycin ophthalmic suspension

Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.

DRUG

Tobramycin and dexamethasone ophthalmic suspension

Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Timothy Comstock, OD · Bausch & Lomb Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00447577 on ClinicalTrials.gov